Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss Syndrome)

  • Christian PagnouxEmail author
  • Loïc Guillevin


Eosinophilic granulomatosis with polyangiitis (EGPA; Churg–Strauss syndrome) is a rare, systemic, necrotizing, small-sized vessel vasculitis. It most typically affects middle-aged individuals who have developed late-onset asthma then more characteristic vasculitis manifestations, like fever, skin lesions (40–75 % of the patients, mainly purpura, often necrotic, and/or cutaneous nodules or papules and sometimes migratory urticarial rashes) and/or mononeuritis multiplex. Blood and tissue eosinophilia, especially the lungs, gastrointestinal tract, and heart, is a hallmark of the disease. Biopsy of an affected organ or lesions, especially skin lesions, can help in making the diagnosis, when showing eosinophilic and/or granulomatous vasculitis, with or without necrosis. Antineutrophil cytoplasm autoantibodies (ANCA) can be detected in nearly 40 % of the patients. Differential diagnoses include drug-induced and hypersensitivity vasculitis, parasitic infections, and hypereosinophilic syndromes. Treatment relies on systemic corticosteroids, combined with an immunosuppressant for severe and/or life-threatening forms.


Erythema Multiforme Hypereosinophilic Syndrome Necrotizing Vasculitis Strauss Syndrome Eosinophilic Fasciitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Churg J, Strauss L. Allergic angiitis and periarteritis nodosa. Am J Pathol. 1951;27:277–301.PubMedGoogle Scholar
  2. 2.
    Pagnoux C, Guillevin L. Churg–Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol. 2010;22:21–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Sinico RA, Bottero P. Churg–Strauss angiitis. Best Pract Res Clin Rheumatol. 2009;23:355–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg–Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26–37.CrossRefGoogle Scholar
  5. 5.
    Keogh KA, Specks U. Churg–Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann Intern Med. 2005;143:632–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthritis Rheum. 2005;52:2926–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Davis MD, Daoud MS, McEvoy MT, Su WP. Cutaneous manifestations of Churg–Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol. 1997;37:199–203.PubMedCrossRefGoogle Scholar
  9. 9.
    Finan MC, Winkelmann RK. The cutaneous extravascular necrotizing granuloma (Churg–Strauss granuloma) and systemic disease: a review of 27 cases. Medicine (Baltimore). 1983;62:142–58.Google Scholar
  10. 10.
    Pagnoux C, Kluger N, Francès C, Guillevin L. Cutaneous granulomatous vasculitis and extravascular granulomas. Expert Rev Dermatol. 2006;1:315–26.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2014

Authors and Affiliations

  1. 1.Division of RheumatologyMount Sinai Hospital/University Health Network, The Rebecca MacDonald Centre for Arthritis and AutoimmunityTorontoCanada
  2. 2.Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique–Hôpitaux de ParisUniversité Paris DescartesParis Cedex 14France

Personalised recommendations